Protagonist Therapeutics Inc (PTGX)

Cash conversion cycle

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Days of inventory on hand (DOH) days 1,707.68 3,789.49 1.32
Days of sales outstanding (DSO) days
Number of days of payables days
Cash conversion cycle days 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,707.68 3,789.49 0.00 0.00 0.00 0.00 0.00 0.00 1.32

December 31, 2024 calculation

Cash conversion cycle = DOH + DSO – Number of days of payables
= — + — – —
= 0.00

The cash conversion cycle of Protagonist Therapeutics Inc has shown fluctuations over the years, with a notable increase to 3,789.49 days as of December 31, 2021. This spike may indicate inefficiencies in the company's management of its working capital and cash flow operations, potentially leading to challenges in converting its investments in inventory and accounts receivable into cash.

Subsequently, the cash conversion cycle improved to 1,707.68 days as of March 31, 2022, suggesting a temporary correction in the company's working capital efficiency. However, the cycle reduced back to 0.00 days in the following periods, indicating that Protagonist Therapeutics has effectively managed its cash flow during those times.

Overall, the company's cash conversion cycle performance reflects varying levels of efficiency in managing its operating cycle components. A longer cash conversion cycle may indicate excessive investments tied up in inventory or slow collections from customers, while a shorter cycle suggests a more streamlined approach in converting its resources into cash.